Relationship between matrix metalloproteinase-2 activity and cystatin C levels in patients with hepatic disease

被引:25
作者
Chen, TY
Hsieh, YS
Yang, CC
Wang, CP
Yang, SF
Cheng, YW
Chiou, HL
机构
[1] Chung Shan Med Univ, Sch Med Technol, Taichung, Taiwan
[2] Chung Shan Med Univ Hosp, Dept Internal Med, Taichung, Taiwan
[3] Chung Shan Med Univ Hosp, Inst Biochem, Taichung, Taiwan
[4] Show Chwan Mem Hosp, Dept Internal Med, Div Gastroenterol, Chunghua, Taiwan
[5] Chung Shan Med Univ Hosp, Dept Lab, Taichung, Taiwan
关键词
MMP-2; cystatin C; hepatic disease;
D O I
10.1016/j.clinbiochem.2005.03.005
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: A direct relationship between cystatin C levels and the severity of hepatic disease has been revealed in our previous study. This study was aimed to consider whether a correlation exists between matrix metalloproteinases (MMPs), which have been proven to be involved in liver cirrhosis, and cystatin C to reflect the severity of hepatic disease. Design and Methods: A total of 154 consecutive patients with various liver diseases were recruited to determine their serum levels of cystatin C, MMP-2 and-9, together with other hepatic parameters. These were compared with 40 normal controls. Results: Average levels of MMP-2 and cystatin C were significantly higher in patients while MMP-9 was significantly lower, as compared to controls. A linear regression analysis has revealed a direct relationship between cystatin C and MMP-2 (Y = 83.39 + 270.56X, R = 0.38, P < 0.001), as well as between MMP-2 and the severity of liver diseases. Conclusion: This is the first study to demonstrate a correlation between cystatin C and MMP-2, suggesting that there may be certain interactions between cystatin C and MMP-2 in patients with hepatic diseases. (C) 2005 The Canadian Society of Clinical Chemists. All rights reserved.
引用
收藏
页码:632 / 638
页数:7
相关论文
共 31 条
[1]  
Arii S, 1996, HEPATOLOGY, V24, P316
[2]   Selective modulation of the secretion of proteinases and their inhibitors by growth factors in cultured differentiated podocytes [J].
Asanuma, K ;
Shirato, I ;
Ishidoh, K ;
Kominami, E ;
Tomino, Y .
KIDNEY INTERNATIONAL, 2002, 62 (03) :822-831
[3]  
BOLLENGIER F, 1987, J CLIN CHEM CLIN BIO, V25, P589
[4]   Increased cystatin C serum concentrations in patients with hepatic diseases of various severities [J].
Chu, SC ;
Wang, CP ;
Chang, YH ;
Hsieh, YS ;
Yang, SF ;
Su, JM ;
Yang, CC ;
Chiou, HL .
CLINICA CHIMICA ACTA, 2004, 341 (1-2) :133-138
[5]   Correlation between plasma levels of matrix metalloproteinase (MMP)-9/MMP-2 ratio and α-fetoproteins in chronic hepatitis carrying hepatitis B virus [J].
Chung, TW ;
Kim, JR ;
Suh, JI ;
Lee, YC ;
Chang, YC ;
Chung, TH ;
Kim, CH .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 (05) :565-571
[6]  
CORTICCHIATO O, 1992, INT J CANCER, V52, P645
[7]  
Ebata M, 1997, LIVER, V17, P293
[8]   Cystatin C as a marker of GFR -: history, indications, and future research [J].
Filler, G ;
Bökenkamp, A ;
Hofmann, W ;
Le Bricon, T ;
Martínez-Brú, C ;
Grubb, A .
CLINICAL BIOCHEMISTRY, 2005, 38 (01) :1-8
[9]  
Hayasaka A, 1996, HEPATOLOGY, V24, P1058
[10]   Tissue inhibitors of metalloproteinases in liver fibrosis [J].
Iredale, JP .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 1997, 29 (01) :43-54